Clear Creek Financial Management’s Pliant Therapeutics PLRX Stock Holding History

Clear Creek Financial Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,000	Closed	-$77K	–	358
2022 Q1	$77K	Buy	11,000 +350	+3%	+$3.57K	0.01%	333
2021 Q4	$144K	Buy	+10,650	New	+$169K	0.02%	341

Other funds holding PLRX

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Clear Creek Financial Management's PLRX Position: Q2 2022 in Review

Clear Creek Financial Management sold out of Pliant Therapeutics (PLRX) in Q2 2022, closing a stake of 11,000 shares — an estimated $77K sold.

Clear Creek Financial Management first reported a position in PLRX in Q4 2021 and held it in 2 quarters. The position peaked at $144K in Q4 2021. 88 funds tracked by Wall St. Rank hold PLRX as of Q2 2022.

Clear Creek Financial Management reported no remaining Pliant Therapeutics position as of Q2 2022 after selling out during the quarter.
Clear Creek Financial Management sold 11,000 Pliant Therapeutics shares in Q2 2022, an estimated $77K.
Clear Creek Financial Management first reported a position in Pliant Therapeutics in Q4 2021 and held it in 2 quarters.
Clear Creek Financial Management's Pliant Therapeutics position peaked at $144K in Q4 2021.
88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2022.

Based on Clear Creek Financial Management's 13F filing for Q2 2022, filed 27 Jul 2022.